Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human antithrombin III heterogeneity.

L Williams, G Murano

    Blood
    |February 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Congenital antithrombin III (AT-III) deficiency in three patients revealed unique crossed immunoelectrophoretic patterns. Patients showed fewer AT-III components compared to normal plasma when analyzed with heparin.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    About stibio-intolerance and stibio-resistance in the treatment of internal leishmaniasis.

    Il Progresso medico·2010
    Same author

    Family adaptation to a child's transplant: pretransplant phase.

    Progress in transplantation (Aliso Viejo, Calif.)·2000
    Same author

    Moving research into community settings in the CSAT methamphetamine treatment project: the coordinating center perspective.

    Journal of psychoactive drugs·2000
    Same author

    Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.

    International journal of cancer·2000
    Same author

    Interleukin 10 modulation of tumour necrosis factor receptors requires tyrosine kinases but not the PI 3-kinase/p70 S6 kinase pathway.

    Cytokine·2000
    Same author

    International Conference on Harmonization--critical discussion of the biotech 'Specifications' document.

    Current opinion in biotechnology·2000

    Area of Science:

    • Biochemistry
    • Immunology
    • Hematology

    Background:

    • Antithrombin III (AT-III) is a crucial protein in the blood coagulation cascade.
    • Congenital AT-III deficiency is a rare genetic disorder associated with an increased risk of thrombosis.
    • Understanding the molecular basis of AT-III deficiency is important for diagnosis and management.

    Purpose of the Study:

    • To investigate the crossed immunoelectrophoretic patterns of antithrombin III (AT-III) in patients with congenital AT-III deficiency.
    • To compare these patterns with those of normal plasma in the presence of heparin.
    • To identify potential differences in AT-III molecular forms associated with deficiency.

    Main Methods:

    • Crossed immunoelectrophoresis was performed on plasma samples from three patients with congenital AT-III deficiency.

    Related Experiment Videos

  • Normal single donor and pooled plasma were used as controls.
  • Heparin was incorporated into the agarose gel to facilitate the separation of AT-III components.

    • Main Results:

    • Normal plasma, in the presence of heparin, separated into four distinct AT-III components: two major and two minor.
    • Patients with congenital AT-III deficiency (approximately 50% of normal levels) exhibited altered patterns.
    • Specifically, deficient patients appeared to possess only one faster-moving and one slower-moving AT-III component.

    Conclusions:

    • Congenital antithrombin III deficiency is associated with distinct alterations in its electrophoretic profile.
    • The observed reduction in AT-III components suggests potential structural or functional abnormalities in the deficient protein.
    • These findings may contribute to a better understanding of the pathophysiology of AT-III deficiency and its thrombotic risk.